BEIJING: February 3 : China's CanSino Biologics Inc. has got the green light to continue phase-3 trials of its Covid-19 vaccine with the support of findings of an independent data monitoring committee, said media reports.

The independent committee "found the drugmaker's (CanSino's covax) Covid-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," the report said. No adverse events related to the vaccine had occurred, according to the Xinhua news agency.

The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc. and the Academy of Military Sciences in China.

CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.

Company Profile: CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua. The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19] The company has previously collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, when CanSino licensed the Canadian Ebola vaccine. As of December 2020, it is currently in Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with over 40,000 people as both a double-dose[11] and single-dose administration.

Janet Yellen discusses pandemic, climate change with World Bank head

India, Pakistan should settle Kashmir Issue In Dignified Manner: Gen Bajwa

Research Finds Oxford/AstraZeneca Shots Drastically Cut Transmission